Titan Pharmaceuticals Inc (TTNP.OQ)
0.95USD
20 Apr 2018
-- (--)
$0.95
--
--
--
--
16,901
$3.10
$0.95
Mon, Apr 2 2018
BRIEF-Titan Pharmaceuticals Q4 Loss Per Share $0.17
* TITAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
BRIEF-Titan Pharmaceuticals Executes Agreement For Acquisition By Molteni Of Probuphine In Europe And Other Territories
* TITAN EXECUTES AGREEMENT FOR ACQUISITION BY MOLTENI OF PROBUPHINE® IN EUROPE AND OTHER SELECT TERRITORIES
BRIEF-Titan Announces Amendment To Horizon Loan Agreement
* TITAN PHARMACEUTICALS INC - ENTRY INTO AN AMENDMENT TO JULY 2017 LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION
BRIEF-Titan Pharmaceuticals Says Co Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio
* TITAN PHARMACEUTICALS INC - ON NOV 27, CO ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING
BRIEF-Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe
* TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE
CORRECTED-BRIEF-European Medicines Agency Accepts Titan's Marketing Application For Probuphine
* EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®
BRIEF-Titan Pharmaceuticals reports Q3 loss per share of $0.20
* Titan pharmaceuticals reports third quarter 2017 financial results
BRIEF-Titan Pharmaceuticals files for offering of up to 280,612 shares by selling stockholder
* Titan Pharmaceuticals Inc files for offering of up to 280,612 shares of co's common stock by the selling stockholder - SEC filing Source text:[http://bit.ly/2izOUEZ] Further company coverage:
- Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q4 2017 Results - Earnings Call Transcript
- Your Daily Pharma Scoop: Omeros' Omidria, Titan Signs Agreement, Reata Announces Top-Line Results
- Wall Street Breakfast: Markets Weighed Down By Cohn Exit
- Wall Street Breakfast: Infrastructure Details Coming Today
- Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q3 2017 Results - Earnings Call Transcript
- Week 41 Breakout Forecast: Short-Term Picks To Give You An Edge